Breast Cancer DetectionNCT07080515
Developing Screening Clinical Breast Examination Implementation Strategies in Nigeria
An observational study of Breast Cancer Detection, run by Yale University at 1 site in Nigeria.
Trial summary
The goal of this observational study is to engage with multilevel stakeholders to collaboratively and to systematically develop a suite of strategies for implementing breast cancer screening using clinical breast examination (CBE) in the primary health centers of Abuja, Nigeria. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Breast Cancer Detection
- How many people
- 62 participants
- Where
- 1 siteNigeria
- Study dates
- 1 Sep 2025to 26 Mar 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: Focus group participants will consist of three categories: screening CBE "adopter" (e.g., clinic administrators/managers, department of health officials, etc), "implementers" (e.g., nurses, physicians, community health workers), and "recipients" (e.g., women from the community eligible for CBE screening and community breast cancer survivors). All participants will be drawn from the two study clinics in Abuja, Nigeria.
In order to be eligible for inclusion in the focus group discussions held with screening CBE "adopters" and "implementers," an individual must meet all of the following criteria:
- Be an employee or volunteer working at a participating PHC OR Be an employee or volunteer working at Nigeria's Ministry of Health OR Be an employee or volunteer working with a non-governmental organization that performs breast cancer related activities within the catchment area of a participating PHC
- Be willing to commit to keeping the content of focus group discussions confidential
In order to be eligible for inclusion in the focus group discussions held with screening CBE "recipients," an individual must meet all of the following criteria:
- Be female
- Be between the ages of 40 and 65 years
- Be living within the catchment area of a participating PHC
- Be willing to commit to keeping the content of focus group discussions confidential
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Developing an Approach to Implementing Breast Cancer Screening Using Clinical Breast Exam in the Primary Health Centers of Abuja, Nigeria
The goal of this observational study is to engage with multilevel stakeholders to collaboratively and to systematically develop a suite of strategies for implementing breast cancer screening using clinical breast examination (CBE) in the primary health centers of Abuja, Nigeria.
The main questions it aims to answer are: What barriers and facilitators exist to conducting screening CBE in Abuja's primary care setting and what implementation strategies would support CBE in primary care clinics?
Participants will:
- Allow observation of study clinic workflows
- Participate in interviews and focus group discussions regarding screening CBE implementation
- Conditions
- Breast Cancer Detection
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Adopters | Individuals responsible for deciding to institute screening CBE in Abuja's primary care clinics (e.g., policymakers, clinic administrators, nurse managers) | |
| Implementers | Individuals responsible for actually performing the screening CBE in Abuja's primary care clinics (e.g., nurses, doctors, fieldworkers, clerical workers) | |
| Recipients | Individuals eligible for a screening CBE (e.g., women over the age of 40 years from the community surrounding study clinics) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Intervention Domain Characteristics
Characteristics of routine clinical breast examination itself that are potential barriers and facilitators to screening implementation, emerging from thematic analysis of qualitative data organized according to the Consolidated Framework for Implementation Research.
Measured: 1 year
Inner Setting Domain Characteristics
Characteristics of the primary care clinics that are potential barriers and facilitators to screening implementation, emerging from thematic analysis of qualitative data organized according to the Consolidated Framework for Implementation Research.
Measured: 1 year
Outer Setting Domain Characteristics
Characteristics of both the community surrounding the clinics and the district-wide health system that are potential barriers and facilitators to screening implementation, , emerging from thematic analysis of qualitative data organized according to the Consolidated Framework for Implementation Research.
Measured: 1 year
Individuals Domain Characteristics
Characteristics of individuals involved in screening that are potential barriers and facilitators to screening implementation, emerging from thematic analysis of qualitative data organized according to the Consolidated Framework for Implementation Research.
Measured: 1 year
Implementation Domain Characteristics
Characteristics of activities and strategies used to implement screening that are potential barriers and facilitators to screening implementation, emerging from thematic analysis of qualitative data organized according to the Consolidated Framework for Implementation Research.
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jul 2025
- Study start1 Sep 2025
- Primary completion26 Mar 2026
- Study completion26 Mar 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast Cancer DetectionStudies of the same condition, open and under way.
- More trials run by Yale UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 62 participants (actual)
Sponsor and investigators
- Lead sponsor
- Yale University
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI), University of Witwatersrand, South Africa
- Responsible party
- Sponsor
- Investigators
- Daniel O'Neil, MD, MPH, Principal investigator, Yale University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07080515
- Sponsor's protocol ID
- 2000040678
- Other IDs
- K08CA279913
- Status last verified
- May 2026
- First submitted
- 30 Jun 2025
- Last updated
- 29 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: In order to comply with local legal requirements, individual participant data will not be available to other researchers.
Study at a glance
From the registry record, last updated by the sponsor on 29 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Developing an Approach to Implementing Breast Cancer Screening Using Clinical Breast Exam in the Primary Health Centers of Abuja, Nigeria
- ClinicalTrials.gov ID
- NCT07080515
- Acronym / sponsor ID
- 2000040678
- Conditions
- Breast Cancer Detection
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 62 participants (actual)
- Lead sponsor
- Yale UniversityUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI), University of Witwatersrand, South Africa
- Study start
- 1 Sep 2025 (actual)
- Primary completion
- 26 Mar 2026 (actual)
- Study completion
- 26 Mar 2026 (actual)
- First posted
- 23 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to engage with multilevel stakeholders to collaboratively and to systematically develop a suite of strategies for implementing breast cancer screening using clinical breast examination (CBE) in the primary health centers of Abuja, Nigeria.
The main questions it aims to answer are: What barriers and facilitators exist to conducting screening CBE in Abuja's primary care setting and what implementation strategies would support CBE in primary care clinics?
Participants will:
- Allow observation of study clinic workflows
- Participate in interviews and focus group discussions regarding screening CBE implementation
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Adopters | – | –Individuals responsible for deciding to institute screening CBE in Abuja's primary care clinics (e.g., policymakers, clinic administrators, nurse managers) |
| Implementers | – | –Individuals responsible for actually performing the screening CBE in Abuja's primary care clinics (e.g., nurses, doctors, fieldworkers, clerical workers) |
| Recipients | – | –Individuals eligible for a screening CBE (e.g., women over the age of 40 years from the community surrounding study clinics) |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Focus group participants will consist of three categories: screening CBE "adopter" (e.g., clinic administrators/managers, department of health officials, etc), "implementers" (e.g., nurses, physicians, community health workers), and "recipients" (e.g., women from the community eligible for CBE screening and community breast cancer survivors). All participants will be drawn from the two study clinics in Abuja, Nigeria.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Intervention Domain Characteristics
Time frame: 1 year
Characteristics of routine clinical breast examination itself that are potential barriers and facilitators to screening implementation, emerging from thematic analysis of qualitative data organized according to the Consolidated Framework for Implementation Research.
Inner Setting Domain Characteristics
Time frame: 1 year
Characteristics of the primary care clinics that are potential barriers and facilitators to screening implementation, emerging from thematic analysis of qualitative data organized according to the Consolidated Framework for Implementation Research.
Outer Setting Domain Characteristics
Time frame: 1 year
Characteristics of both the community surrounding the clinics and the district-wide health system that are potential barriers and facilitators to screening implementation, , emerging from thematic analysis of qualitative data organized according to the Consolidated Framework for Implementation Research.
Individuals Domain Characteristics
Time frame: 1 year
Characteristics of individuals involved in screening that are potential barriers and facilitators to screening implementation, emerging from thematic analysis of qualitative data organized according to the Consolidated Framework for Implementation Research.
Implementation Domain Characteristics
Time frame: 1 year
Characteristics of activities and strategies used to implement screening that are potential barriers and facilitators to screening implementation, emerging from thematic analysis of qualitative data organized according to the Consolidated Framework for Implementation Research.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 May 2026.
- Individual participant dataSharing planned: No. In order to comply with local legal requirements, individual participant data will not be available to other researchers.
Related trials for Breast Cancer Detection
RecruitingPhase 2
Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy
Breast Cancer Metastatic, Breast Cancer Stage IV
RecruitingObservational study
Avera Cancer Sequencing and Analytics Protocol (ASAP)
Cancer, Cancer Diagnosis
RecruitingObservational study
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
RecruitingObservational study
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
Breast Cancer
RecruitingObservational study
Post-market Safety Study of LUMISIGHT
Hypersensitivity Reactions
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Daniel O'Neil, MD, MPH principal investigator
Yale University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Breast Cancer Detection, run by Yale University at 1 site in Nigeria.
The full registered description is in the About this study section and the official record.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Nigeria. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Intervention Domain Characteristics (time frame: 1 year). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 May 2026.